Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

SkinCeuticals

Also known as: skinceuticals, skin ceuticals, c e ferulic, ce ferulic

SkinCeuticals is a US professional skincare brand founded in 1994 and acquired by L'Oréal in 2005. It grew from Sheldon Pinnell's Duke University research on low-pH L-ascorbic acid formulations. Its UK serums, peels and other products are cosmetics rather than medicines.

Evidence status

Manufacturer-supported

C E Ferulic has human adjunct and photoprotection studies, but much of its foundational absorption and dose evidence comes from pig skin, and several key papers are manufacturer-authored or commercially connected. No independent head-to-head trial against a matched generic 15% vitamin C, 1% vitamin E and 0.5% ferulic formula was located, so the evidence does not establish brand superiority. Formulation-level findings should not be generalised to vitamin C as an ingredient class.

What SkinCeuticals is, and the ranges available#

SkinCeuticals is a US professional skincare brand. L'Oréal's acquisition release describes it as founded in 1994, headquartered in Dallas and sold through dermatologists, plastic surgeons and high-end spas, with 2004 sales of US$35 million. L'Oréal signed the acquisition agreement in May 2005 for its then Active Cosmetics division, now Dermatological Beauty.[6][6]

There is no UK company named SkinCeuticals. The brand reaches Britain through L'Oréal's corporate structure; Companies House records L'Oréal (U.K.) Limited, company 00271555, as the active UK group entity, though the exact Article 4 Responsible Person should be read from the product pack.[14]

The origin story centres on Duke dermatologist Sheldon Pinnell. He was a named inventor on Duke's stable-ascorbic-acid patent and on the later L'Oréal USA-assigned C E Ferulic patent, and disclosed that he was a SkinCeuticals consultant. Academic authorship and commercial interest are both part of the record.[3, 4, 5]

C E Ferulic is the flagship antioxidant serum: 15% L-ascorbic acid, 1% DL-alpha-tocopherol and 0.5% trans-ferulic acid. The 2005 experimental composition and 2025 marketed-serum description match on those three actives.[3, 5, 8]

The brand also sells other antioxidants, correctives, sunscreens and professional peels. Evidence for one formula does not transfer to the entire range.

Use of SkinCeuticals in aesthetic practice#

SkinCeuticals products are cosmetics in Great Britain. Assimilated Regulation (EC) No 1223/2009 governs safety assessment, Responsible Person, Product Information File and notification; the 2013 Enforcement Regulations provide enforcement. There is no pre-market efficacy approval, MHRA medicines authorisation or legal category of “cosmeceutical” or “medical-grade skincare”.[12]

Claims repeated by a clinic must meet the common criteria in assimilated Regulation (EU) No 655/2013, including evidential support. A pig-skin absorption or irradiation model can be described as such; presenting it as a measured human clinical outcome changes the evidence.[3, 13]i

Chemical peels sit within the JCCP/CPSA skin-rejuvenation modality; retail antioxidant serums do not acquire a separate competence standard from professional-channel sale. England's 2023 licensing tiers remain proposals and the 2025 response did not assign procedures. Scotland's 2026 Act is not fully in force; Welsh special-procedure licensing does not cover ordinary cosmetic retail.[12, 13]

The US patents and any American professional positioning carry no UK regulatory permission.

Contraindications and cautions#

Contraindications depend on the exact SkinCeuticals formula, skin state, concurrent actives and planned procedure. The current product directions govern.

Low-pH L-ascorbic acid formulas can sting or irritate, especially on already inflamed or barrier-impaired skin. C E Ferulic's pH and solvent system are part of the studied formulation, so tolerability cannot be inferred from “15% vitamin C” alone.[1, 3]

Post-laser or post-radiofrequency use is a separate decision. Positive adjunct trials do not establish suitability after every energy device, intensity, skin type or complication. The procedure-device instructions and named product protocol govern timing.

Photoprotection claims do not make C E Ferulic a sunscreen substitute. The experimental studies used pre-irradiation antioxidant application under controlled conditions and did not measure real-world sunscreen replacement.[3, 7]

Clinical uses and the evidence behind them#

Formulation and photoprotection research

The 2001 absorption study produced two widely repeated formulation rules: L-ascorbic acid entered pig skin when formulated below pH 3.5, and skin levels increased up to 20% concentration. Tissue levels saturated after three daily applications and declined with an approximate four-day half-life. These were pig tissue concentrations, not human clinical endpoints.[1, 3][1]

The same experiment found that magnesium ascorbyl phosphate, ascorbyl-6-palmitate and dehydroascorbic acid did not increase tissue L-ascorbic acid. It did not compare finished derivative products or establish clinical inferiority.[1]

In 2005, adding 0.5% ferulic acid to 15% vitamin C plus 1% vitamin E increased the antioxidant protection factor from about four-fold to eight-fold in six weanling white Yorkshire pigs after four applications and acute solar-simulated irradiation. Ferulic acid alone produced about four-fold protection, matching vitamin C plus E in that model, so it contributed more than stabilisation alone.[3][3]

An earlier pig study from the same group found experimental UV photoprotection from combined topical vitamins C and E. It supports the antioxidant pairing in that model, not a human clinical protection factor.[2]

A later Duke human study applied the 15/1/0.5 formula and vehicle to normal-appearing skin for four days before controlled UV exposure and reported significant protection across erythema, sunburn cells, thymine dimers, p53 and cytokines. The abstract states that the sample was relatively small but does not disclose its denominator or effect sizes, and the full text was unavailable.[7]

Post-procedure adjunctive evidence

Modern brand-specific studies mainly assess C E Ferulic after procedures. A 50-person split-face randomised trial found lower day-seven erythema after non-ablative fractional laser (0.04 versus 0.18, p=0.011). A 15-person vehicle-controlled split-face study found less oedema and erythema after ablative carbon-dioxide resurfacing. A 31-person split-neck placebo-controlled trial after fractional microneedle radiofrequency reported greater wrinkle reduction at 12 weeks (29.9% versus 18.0%), elasticity gain (12.9% versus 2.3%), GAIS improvement (87.5% versus 14.3%) and histological changes.[8, 9, 10][8, 9, 10]

These are positive product-specific signals with small samples and procedure-specific protocols. The largest trial was L'Oréal-funded; the 2025 neck trial included SkinCeuticals employees and an industry grant. They did not compare C E Ferulic with another active antioxidant serum.[10][3, 8, 9]

Standalone ageing claims

A systematic review screened 5,428 records from 2015 to 2022 and found seven eligible topical-vitamin-C wrinkle studies. Every study combined vitamin C with other ingredients, preventing vitamin C-specific conclusions.[11]

That does not negate C E Ferulic's formulation or adjunct data. It limits what can be attributed specifically to vitamin C and prevents a broad claim of independent superiority.

Selecting a SkinCeuticals product#

Selection distinguishes the exact formula from the ingredient class. C E Ferulic has matched active percentages across the seminal and marketed descriptions; another L-ascorbic acid serum may differ in pH, solvent, packaging and stability, while a derivative serum answers a different question.[3, 8]

The 20% figure is not a universal product optimum. It came from pig absorption data, while the flagship formula is 15%. No located human head-to-head study compares 15% with 20% C E Ferulic or a matched generic formula.[1, 3]i

Patent status does not identify present quality. Duke's low-pH ascorbic-acid patent expired in 2009; the separate L'Oréal USA C E Ferulic composition patent expired in March 2025. The formula is no longer protected merely by invoking “the Duke patent”.[4, 5]

For post-procedure selection, the exact procedure, device settings, skin condition and named study population matter. The current manufacturer directions govern application and timing. Skinipedia does not publish a generic post-procedure antioxidant protocol.

Adverse effects and their management#

Expected local effects

Low-pH antioxidant formulas may cause transient stinging, dryness or erythema. After a procedure, these effects can overlap with the procedure's own inflammatory response, so product and procedure exposures remain separately documented.

Post-procedure findings

The small adjunct trials reported reductions in selected erythema or oedema outcomes rather than elimination of recovery effects. Their denominators are too small to quantify uncommon harms, and a favourable average does not authorise use on compromised, infected or unexpectedly inflamed skin.[8, 9, 10]

Persistent or unexpected reactions

Escalating pain, blistering, prolonged inflammation, infection, delayed healing, allergy or progressive pigment change requires cessation, assessment and use of the relevant product and device reporting routes.

Referral and scope boundaries#

SkinCeuticals cosmetics do not treat a medical diagnosis by regulatory status. Suspected dermatitis, infection, unexplained pigment change, severe acne, delayed healing or another presentation requiring diagnosis is referred appropriately.

A post-procedure reaction exceeding the expected course, eye exposure with persistent symptoms, systemic allergy or suspected deep injury needs clinical assessment. The referral record should include the exact serum, lot, procedure, device, timing and all concurrent products.

Mechanism of action#

L-ascorbic acid and alpha-tocopherol act as antioxidants, while ferulic acid can contribute antioxidant activity and improve formula stability. In the 2005 pig model, ferulic acid alone matched the protection of vitamins C and E together and did not appreciably increase ascorbic-acid absorption.[3]

Formulation below pH 3.5 improved pig-skin uptake of L-ascorbic acid. That mechanistic model supports formulation plausibility but does not quantify real-world human photoprotection or replace sunscreen.[1, 3, 7]

Commonly misstated claims#

“C E Ferulic doubles human sun protection”

The four-fold to eight-fold result was measured in six pigs under acute simulated irradiation. A separate small human study supports a signal but reports no comparable protection factor in its abstract.[3, 7]

Supported statement: the 15/1/0.5 formula improved experimental photoprotection in pigs and showed photoprotective biomarkers in one small human study.

“The formula is protected by the Duke patent”

The Duke patent covered low-pH ascorbic acid and expired in 2009. The separate C E Ferulic patent was assigned to L'Oréal USA and expired in 2025.[4, 5]

Supported statement: the formulation arose from patented work, and both identified US patents have expired.

“Twenty per cent vitamin C is the proven optimum”

Twenty per cent was the absorption ceiling in pig skin, with no clinical endpoint; C E Ferulic itself uses 15%.[1, 3]

Supported statement: pig absorption rose up to 20%, while the studied C E Ferulic formula contains 15% L-ascorbic acid.

“Vitamin C derivatives do not work”

Three derivatives did not increase tissue L-ascorbic acid in one pig study. That is not comparative clinical evidence against all derivative formulations.[1]

Supported statement: those derivatives failed one L-ascorbic-acid uptake endpoint in the originating pig model.

Areas of remaining uncertainty#

  • The small human photoprotection study's denominator, methods and disclosures were unavailable; this limits quantification of the human effect.
  • No human trial compares 15% with 20% of the same formulation; this prevents calling either a universal optimum.
  • Ferulic acid's relative contribution through stability and direct antioxidant action is unresolved; this limits simplified mechanism claims.
  • Post-procedure trials lack an active antioxidant comparator; this prevents attributing benefit uniquely to SkinCeuticals rather than a well-formulated class alternative.
  • No independent matched-formula head-to-head trial was located; this prevents an evidence-based superiority claim over generic 15/1/0.5 serums.

Frequently asked questions#

Is C E Ferulic a sunscreen?

No. It is an antioxidant cosmetic. Experimental photoprotection does not replace a regulated sunscreen or ordinary sun-protection measures.[3, 7]

Is the 20% vitamin C rule based on humans?

No. It came from a pig-skin absorption study.[1]

Is SkinCeuticals medical-grade?

That is a marketing term, not a GB legal category. The products are cosmetics.[12]

Is C E Ferulic still patented?

The two identified underpinning US patents have expired.[4, 5]

What timing applies around procedures?

The instructions for the exact product and procedure govern. The positive studies used named procedures and protocols; Skinipedia does not generalise them.[8, 9, 10]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Pinnell SR, Yang H, Omar M, Monteiro-Riviere N, DeBuys HV, Walker LC, Wang Y, Levine M. Topical L-ascorbic acid: percutaneous absorption studies. Dermatol Surg. 2001 Feb;27(2):137-42.Animal studyTier 3Supports: This is the origin of the two numbers the whole brand rests on, and it is a PIG study. Methods, verbatim from the abstract: 'L-ascorbic acid or its derivatives were applied to pig skin. Skin levels of L-ascorbic acid were measured to determine percutaneous delivery.' Results, verbatim: 'L-ascorbic acid must be formulated at pH levels less than 3.5 to enter the skin. Maximal concentration for optimal percutaneous absorption was 20%. Tissue levels were saturated after three daily applications; the half-life of tissue disappearance was about 4 days. Derivatives of ascorbic acid including magnesium ascorbyl phosphate, ascorbyl-6-palmitate, and dehydroascorbic acid did not increase skin levels of L-ascorbic acid.' Scope limits: porcine skin only; no human subjects; no clinical endpoint (no wrinkle, pigment or erythema outcome) - this is an absorption study. Animal numbers and statistical detail are not given in the abstract and the full text was not retrievable.Funding / interest: The funding and disclosure statement printed with this specific paper was not retrievable (paywalled). Two commercial interests are documented from outside it. First, senior author Sheldon Pinnell is a named inventor on both the Duke ascorbic-acid patent and the later L'Oreal USA-assigned patent (sources 4 and 5), and disclosed a SkinCeuticals consultancy in a 2005 paper from the same laboratory (source 3). Second, co-author 'Omar M' is Mostafa M. Omar, who per NIH RePORTER was principal investigator on NIH SBIR Phase I grant R43CA83538 ('Prevention of UV photoinjury in skin by antioxidants', FY2000, $100,000) held by Phytoceuticals Inc., Elmwood Park, New Jersey - a commercial company. That grant is the one acknowledged in the 2005 ferulic acid paper (source 3). Verified 2 August 2026 via the NIH RePORTER API.
  2. Lin JY, Selim MA, Shea CR, Grichnik JM, Omar MM, Monteiro-Riviere NA, Pinnell SR. UV photoprotection by combination topical antioxidants vitamin C and vitamin E. J Am Acad Dermatol. 2003 Jun;48(6):866-74.Animal studyTier 3Supports: Establishes the 15% L-ascorbic acid + 1% alpha-tocopherol base and its 4-fold antioxidant protection factor. Verbatim methods: 'We developed a stable aqueous solution of 15% L-ascorbic acid (vitamin C) and 1% alpha-tocopherol (vitamin E). We applied antioxidant or vehicle solutions to pig skin daily for 4 days. We irradiated (1-5x minimal erythema dose) control- and antioxidant-treated skin using a solar simulator with a 295-nm band-pass filter.' Result: 'Application during 4 days provided progressive protection that yielded an antioxidant protection factor of 4-fold.' Also reported protection against thymine dimer formation. Scope limits: pig skin, 4-day pre-treatment, acute UV challenge only; says nothing about chronic use, photoageing outcomes or human skin.Funding / interest: Duke University Medical Center laboratory of Sheldon Pinnell, who is a named inventor on the ascorbic-acid patents (sources 4 and 5) and a disclosed SkinCeuticals consultant (source 3). The paper's own disclosure statement was not retrievable. Co-author 'Omar MM' is Mostafa M. Omar of Phytoceuticals Inc., the commercial holder of NIH SBIR grant R43CA83538 acknowledged in the 2005 successor paper (source 3); this affiliation is not visible in the PubMed record for this paper.
  3. Lin FH, Lin JY, Gupta RD, Tournas JA, Burch JA, Selim MA, Monteiro-Riviere NA, Grichnik JM, Zielinski J, Pinnell SR. Ferulic acid stabilizes a solution of vitamins C and E and doubles its photoprotection of skin. J Invest Dermatol. 2005 Oct;125(4):826-32.Animal studyTier 3Supports: The C E Ferulic paper. Formulation, verbatim: '15% L-ascorbic acid, 1% DL-alpha-tocopherol, 0.5% trans ferulic acid', in 'a vehicle containing diethylene glycol monoethyl ether, 1,2-propanediol, Brij-35, and phenoxyethanol at pH 3'. Species, verbatim from Materials and Methods: 'Experiments were performed on weanling white Yorkshire pigs' - this is an ANIMAL study, not human. n=6 per figure legend. Results: both 0.5% ferulic acid ALONE and 15% C + 1% E together gave 'about 4-fold protection'; the three-way combination gave 'approximately 8-fold protection' and was statistically different from either (*p<0.01). Skin was irradiated from 2x to 10x MED at 2x MED intervals; the triple combination differed statistically from control and vehicle at all MED tested, from ferulic acid alone at 2x, 6x and 8x MED by colorimetry, and from vitamins C+E at 4x and 6x MED by colorimetry, with sunburn cell counts differing from both comparators at 2x, 4x, 6x and 8x MED. Also reduced caspase-3/caspase-7 activation and thymine dimer formation. Honest positives: the doubling effect is real and statistically significant in this model, and the paper reports 'It had no appreciable effect on ascorbic acid absorption (data not shown)', so the benefit is attributed to antioxidant activity rather than penetration. The paper also explicitly positions the product alongside, not instead of, sunscreen: 'Using both a properly formulated topical combination antioxidant product containing vitamins C and E with ferulic acid, and also a broad-spectrum sunscreen, would be expected to provide optimal photoprotection. Since they work by different mechanisms, they should be supplemental.' Scope limits: porcine skin, acute solar-simulated irradiation, 4 days of application, no clinical ageing endpoint, no human data. Full text read directly on 2 August 2026.Funding / interest: Disclosure printed in the paper, verbatim: 'Sheldon Pinnell is a consultant for SkinCeuticals, Garland, Texas. Jan Zielinski, PhD is president of Zielinski Laboratory, San Diego, California.' Pinnell and Zielinski are the two named inventors on the C E Ferulic patent (source 5). The acknowledgments also state, verbatim: 'This research was supported in part by NIH Grant R43CA83538.' The R43 mechanism is SBIR Phase I, awarded to small businesses rather than universities: NIH RePORTER records 1R43CA083538-01A1, 'Prevention of UV photoinjury in skin by antioxidants', FY2000, awarded to Phytoceuticals Inc. (Elmwood Park, New Jersey) with principal investigator Mostafa M. Omar, who is a co-author on sources 1 and 2. The paper does not disclose this commercial character of the cited grant.
  4. US Patent 5,140,043 A, 'Stable ascorbic acid compositions'. Inventors: Douglas Darr, Sheldon R. Pinnell. Original assignee: Duke University Medical Center; current assignee: Duke University. Filed/priority 17 April 1989; granted 18 August 1992.Tier 1Supports: The actual 'Duke patent'. Claim 1, verbatim: 'A topical composition consisting essentially of from at least about 1% ascorbic acid (w/v) in water and a carrier suitable for topical application wherein the ratio of water to carrier is at least 1:1 and wherein the composition has a pH of no more than about 3.5.' Stated ranges: minimum 1% w/v ascorbic acid, preferred 3-20% w/v, most preferred 5-10% w/v; pH no more than about 3.5, preferably 2.5 or below. Status on the register: 'Expired - Lifetime', anticipated expiration 18 August 2009. Scope limits: a patent establishes novelty and legal ownership, not clinical efficacy; it carries no evidential weight for outcomes. Note that this Duke patent covers ascorbic acid at low pH generally - it is NOT the C E Ferulic patent (see source 5).Funding / interest: Assigned to Duke University; Pinnell, the Duke academic whose published research underpinned the formulations, is a named inventor and therefore had a direct financial interest in the patent estate.
  5. US Patent 7,179,841 B2, 'Stabilized ascorbic acid compositions and methods therefor'. Inventors: Jan E. Zielinski, Sheldon R. Pinnell. Original assignee: L'Oreal USA Creative Inc; current assignee: L'Oreal USA S.D. Inc. Priority date 13 January 2004; filed 11 January 2005; granted 20 February 2007.Tier 1Supports: The C E Ferulic patent. The independent claim covers a single-phase solution containing L-ascorbic acid '5% to 40%' by weight; a cinnamic acid derivative (p-coumaric acid, ferulic acid, caffeic acid or sinapinic acid) at '0.2% to 5.0%' by weight; a glycol ether/alkanediol solvent system at '10% to 60%' by weight; water; and pH 'no more than about 3.5'. Worth noting for practice: tocopherol (vitamin E) does not appear in the independent claim at all - the claimed invention is the ascorbic acid plus cinnamic-acid-derivative plus glycol-ether/alkanediol solvent system, so the patent is narrower than the marketed 'C, E and ferulic' story. Register status: 'Expired - Lifetime', expiry 24 March 2025. Two facts here matter for practice: the assignee is L'Oreal USA, not Duke, and the patent is now expired, so the composition is no longer protected. Scope limits: legal document only; no efficacy weight.Funding / interest: Assigned to L'Oreal USA (owner of SkinCeuticals). Sheldon Pinnell, the academic author of the supporting studies, is a named co-inventor - a direct commercial interest in the formulation his research supported.
  6. L'Oreal. News release: 'L'Oreal to acquire SkinCeuticals'. Clichy, Wednesday 18 May 2005, 7.00 p.m.Tier 4Supports: Primary corporate source, quoted verbatim: 'L'Oreal, the world's largest beauty company, announced today that it has signed an agreement to acquire SkinCeuticals, a professional skin care company. Founded in 1994 and headquartered in Dallas, Texas, SkinCeuticals, a privately held company, is one of the largest and fastest growing brands in the professional premium skin care market in the U.S. Through a strong and specialized distribution network, the company sells to dermatologists, plastic surgeons, and high end spas. SkinCeuticals sales in 2004 amounted to 35$M.' Also verbatim: 'SkinCeuticals will be part of the Active Cosmetics Division of L'Oreal', and a quote attributed to 'Alden Pinnell, co-founder of SkinCeuticals'. Scope limits: a corporate announcement of a signed agreement subject to 'customary closing conditions, including antitrust clearance'; it states the founding year as 1994, which conflicts with the 1997 date widely repeated in trade press and by the brand's own marketing.Funding / interest: Issued by L'Oreal, the acquiring party and current owner of SkinCeuticals. Self-interested corporate communication.
  7. Murray JC, Burch JA, Streilein RD, Iannacchione MA, Hall RP, Pinnell SR. A topical antioxidant solution containing vitamins C and E stabilized by ferulic acid provides protection for human skin against damage caused by ultraviolet irradiation. J Am Acad Dermatol. 2008 Sep;59(3):418-25.Tier 3Supports: The only human in-vivo study from the originating group, and the reason the photoprotection claim is not purely animal. Verbatim objective: 'to determine whether a stable topical formulation of 15% L-ascorbic acid, 1% alpha-tocopherol, and 0.5% ferulic acid (CEFer) could protect human skin in vivo from substantial amounts of solar-simulated UV radiation.' Method: CEFer and vehicle applied to separate patches of normal-appearing human skin for 4 days, then irradiated at 2 to 10 minimal erythema doses at 2-MED intervals; assessed at 1 day for erythema, sunburn cells, thymine dimers, p53 and cytokines (IL-1alpha, IL-6, IL-8, IL-10, TNF-alpha) by real-time PCR. Result as stated: 'CEFer provided significant and meaningful photoprotection for skin by all methods of evaluation.' The paper's own stated limitation, verbatim: 'The number of patients evaluated was relatively small.' Scope limits: the abstract does not give the number of subjects, and no effect sizes are reported in it; the full text was not retrievable, so n, randomisation, blinding and the disclosure statement are unverified. Acute UV-challenge model with a 4-day application - not a photoageing or skin cancer outcome study, despite the discussion inviting that inference.Funding / interest: Duke University Medical Center; senior author Sheldon Pinnell, a named patent inventor (sources 4, 5) and disclosed SkinCeuticals consultant (source 3). The paper's own disclosure text could not be retrieved.
  8. Qin X, Zhai J, Zhou C, Wang Y, Chen M, Zhu L, Shi Q, Chen W, Zhang L, Luo X, Li K. A randomized, investigator-blinded, split-face, controlled trial assessing efficacy and satisfaction of CE Ferulic serum following nonablative fractional Fraxel laser treatment for photoaging skin in Chinese population. J Cosmet Dermatol. 2025 May;24(5):e70251.Tier 2Supports: The largest named-product RCT located. Design: randomised, investigator-blinded, split-face; 50 patients (45/50 female), mean age 31.6 years, mild-to-moderate facial photodamage; CE Ferulic to one side and normal saline to the other immediately after non-ablative fractional laser and daily for 7 days. Registered ChiCTR2300069246. Primary endpoint met: mean change from baseline in erythema score at day 7 was 0.04 +/- 0.40 (CEF) vs 0.18 +/- 0.48 (saline), p = 0.011. Erythema index at day 7: -4.05% +/- 22.12% vs +5.72% +/- 20.41%, p < 0.001. Melanin index day 3 difference -7.16% +/- 17.15%, p = 0.005. Skin hydration favoured CEF at day 1 (+9.53% +/- 24.37%, p = 0.007) and day 3 (+11.80% +/- 24.94%, p = 0.002). Scope limits: 7-day post-procedure recovery study in a young Chinese cohort with a saline comparator (not a vehicle), so a formulation/occlusion effect cannot be excluded; absolute differences are small; nothing here addresses long-term anti-ageing or photoprotection.Funding / interest: Verbatim from the paper: 'L'Oreal provided funding for the trial. Study materials (CE Ferulic serum) were provided by SkinCeuticals Inc.'
  9. Kim J, Lee SG, Boo J, Kim H, Hwang S, Liu C, Yan X, Brieva P, Kim J. Fractional microneedle radiofrequency with the application of vitamin C, E, and ferulic acid serum for neck skin rejuvenation: a prospective, double-blinded, split-neck, placebo-controlled trial. J Dermatolog Treat. 2025 Dec;36(1):2504655.Tier 2Supports: Prospective, randomised, double-blind, split-neck, placebo-controlled; 31 participants aged 30-65 with visible neck ageing; two fractional microneedle radiofrequency treatments 4 weeks apart, then daily antioxidant serum to one randomised side and placebo to the other. At week 12 the serum side showed greater wrinkle severity reduction (29.9% vs 18.0%, p < 0.001), greater elasticity increase (12.9% vs 2.3%, p < 0.001) and higher GAIS improvement (87.5% vs 14.3%); histology showed increased elastin and reduced senescence markers p16 and gamma-H2A.X. This is the strongest positive brand-linked result located and should not be dismissed. Scope limits: n=31, single centre, 12 weeks, neck only, and the serum is tested as an adjunct to an energy device rather than alone - the design cannot tell you what the serum does on its own.Funding / interest: Two authors, Xi Yan and Patricia Brieva, are affiliated to 'SkinCeuticals, New York, NY, USA' per the published author information - i.e. brand employees are co-authors on the trial. Grant funding recorded against the paper in Europe PMC: Yonsei University Faculty Research Grants 6-2024-0056 and 6-2023-0098, and Yonsei University Industry Grant 3-2024-0157. The 'industry grant' line is not itemised further in the record retrieved, and the full disclosure-of-interest statement (tandfonline) returned HTTP 403, so the sponsor behind that industry grant is unverified.
  10. Waibel JS, Mi QS, Ozog D, Qu L, Zhou L, Rudnick A, Al-Niaimi F, Woodward J, Campos V, Mordon S. Laser-assisted delivery of vitamin C, vitamin E, and ferulic acid formula serum decreases fractional laser postoperative recovery by increased beta fibroblast growth factor expression. Lasers Surg Med. 2016 Mar;48(3):238-44.Tier 2Supports: Double-blinded, prospective, single-centre, randomised split-face trial; 15 healthy men and women aged 30-55; serum applied to one side of the face and vehicle to the other within 2 minutes of fractional ablative CO2 laser resurfacing and daily during healing; evaluated daily days 1-7. Results: decreased oedema vs vehicle on day 7 and decreased erythema vs vehicle on days 3 and 5; bFGF expression significantly increased at day 5 on the treated side. Vehicle-controlled design is a methodological strength relative to source 8. Scope limits: n=15, 7 days, wound-healing endpoints only; the product is identified in the abstract only by internal formula code '#740019', not by brand name, so brand attribution rests on the composition rather than on a labelled product; effect sizes and p-values are not given in the abstract.Funding / interest: The funding and conflict-of-interest statement was not retrievable (paywalled). The use of an internal formula code is consistent with industry-supplied material, but this was not verified and should not be asserted.
  11. Sanabria B, Berger LE, Mohd H, Benoit L, Truong TM, Michniak-Kohn BB, Rao BK. Clinical efficacy of topical vitamin C on the appearance of wrinkles: a systematic literature review. J Drugs Dermatol. 2023 Sep 1;22(9):898-904.Tier 1Supports: Systematic literature review of Scopus, Web of Science and PubMed for January 2015 to September 2022. (The package originally called this 'PRISMA-guided'; the abstract retrieved does not state PRISMA adherence and the full text is paywalled, so that descriptor has been dropped.) After deduplication and screening, '5,428 initial records were reduced to 7 articles, including 4 meeting Level IB criteria, one meeting Level IIA criteria, and 2 meeting Level IIB criteria.' Conclusion, verbatim: 'While 4 of the 7 studies met Level IB evidence, further high-quality, prospective, and comparative studies are indicated to better elucidate the role of topical vitamin C in wrinkle reduction. All the studies used vitamin C in combination with other ingredients or therapeutic mechanisms, thereby complicating any specific conclusions regarding the efficacy of vitamin C.' Scope limits: this reviews the active class, not the brand, and covers wrinkle appearance only - not photoprotection, pigment or post-procedure recovery. Used here to characterise the density of the surrounding evidence base, not to score any SkinCeuticals product.Funding / interest: Not retrievable: the JDD full text is paywalled and the abstract record carries no funding or conflict-of-interest statement. Senior author Bijan K. Rao (Rao BK) publishes widely in cosmetic dermatology; no disclosure could be verified either way.
  12. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast), as assimilated law applying in Great Britain; enforced by the Cosmetic Products Enforcement Regulations 2013 (SI 2013/1478).Tier 1Supports: The legal frame for every SkinCeuticals product sold in GB. legislation.gov.uk maintains the GB version as retained/assimilated EU law with amendments made since IP completion day (31 December 2020); the version consulted was current to 1 August 2026. Relevant articles by title: Article 3 Safety; Article 4 Responsible person; Article 5 Obligations of responsible persons; Article 10 Safety assessment; Article 11 Product information file. The Cosmetic Products Enforcement Regulations 2013 set the GB enforcement regime, with enforcement authorities under regulation 6 and market-surveillance, entry, seizure and detention powers under regulation 7 and Schedule 2. Scope limits: this is a product-safety regime, not an efficacy regime - nothing in it requires a cosmetic to work, and there is no pre-market approval or licensing body for cosmetics equivalent to MHRA marketing authorisation for medicines.Funding / interest: Not applicable: primary legal instrument / public register. No sponsor, no author disclosure. Consulted directly on legislation.gov.uk and Companies House; re-verified 2 August 2026.
  13. Commission Regulation (EU) No 655/2013 of 10 July 2013 laying down common criteria for the justification of claims used in relation to cosmetic products, as assimilated law applying in Great Britain.Tier 1Supports: Sets six common criteria for cosmetic claims: legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making. 'Evidential support' requires claims to be substantiated by adequate and verifiable evidence consistent with current knowledge. This is the provision under which a UK clinic repeating brand claims about photoprotection, collagen or 'medical-grade' status can be challenged. Scope limits: applies to claims made about the cosmetic product; it does not validate any specific study, and it does not stop a clinic making a claim - it only makes an unsubstantiated one unlawful.Funding / interest: Not applicable: primary legal instrument / public register. No sponsor, no author disclosure. Consulted directly on legislation.gov.uk and Companies House; re-verified 2 August 2026.
  14. Companies House register records for 'SkinCeuticals' and 'L'Oreal UK'. Accessed 1 August 2026.Tier 1Supports: A search of the UK register for 'skinceuticals' returned no results: there is no UK-registered company of that name. The relevant active UK L'Oreal entity on the register is L'OREAL (U.K.) LIMITED, company number 00271555, incorporated 24 December 1932, registered office Gateway Central, 187 Wood Lane, London, W12 7SA, status Active. Scope limits: the register shows corporate registration only. It does not identify which L'Oreal group entity acts as the 'responsible person' under Article 4 of the assimilated Cosmetics Regulation for SkinCeuticals products placed on the GB market; that was not verified.Funding / interest: Not applicable: primary legal instrument / public register. No sponsor, no author disclosure. Consulted directly on legislation.gov.uk and Companies House; re-verified 2 August 2026.